Evidence map›Paper›PMID 41488503›Full record

ArticleRSC advances2025

Multicomponent synthesis of novel imidazole-pyran derivatives:

Zahra Jamshidi, Seyed Mohammad Taghdisi, Khalil Abnous, Razieh Ghodsi, Farzin Hadizadeh

Abstract read
In one paragraph

Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Zahra JamshidiDepartment of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences Mashhad Iran hadizadehf@mums.ac.ir +98 51 38823251 +98 51 31801128.
Seyed Mohammad TaghdisiTargeted Drug Delivery Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences Mashhad Iran.ORCID https://orcid.org/0000-0001-9836-2189
Khalil AbnousDepartment of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences Mashhad Iran hadizadehf@mums.ac.ir +98 51 38823251 +98 51 31801128.ORCID https://orcid.org/0000-0001-6314-0164
Razieh GhodsiDepartment of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences Mashhad Iran hadizadehf@mums.ac.ir +98 51 38823251 +98 51 31801128.
Farzin HadizadehDepartment of Medicinal Chemistry, School of Pharmacy, Mashhad University of Medical Sciences Mashhad Iran hadizadehf@mums.ac.ir +98 51 38823251 +98 51 31801128.ORCID https://orcid.org/0000-0002-7680-8191

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Herein, a three-component reaction was used for the synthesis of imidazole-pyran derivatives (4a-n) through the reaction between imidazol-5-carbaldehyde (1a-n), malononitrile (2), and methyl acetoacetate (3). The reaction process was simple, quick, proceeded without the need for any purification technique and used green solvents. The synthesized substances (4a-n) were evaluated for their potential anticancer effects on the MCF-7 (breast cancer), HT29 (colon cancer), and A2780cis (cisplatin-resistant ovarian cancer) cell lines, and a control normal cell line, CHO (Chinese hamster ovary). Notably, compounds 4e and 4h demonstrated pronounced effects on the MCF-7 cell line, with an IC

Identifiers

PMID41488503
PMCPMC12757938

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.